

PROGRESSIVE'S EVENING STROLL

DATE: 01 June, 2026

Market Snapshot:

Despite a strong start, the Index once again erased all its gains during the opening trade. As regular intervals, it compounded its losses and eventually closed the trade at 23,382.60, down 165.15 points. Among the sectors, IT was the top performer, followed by Media, while FMCG and Defence were the major laggards. In the broader markets, Mid and Smallcaps declined by 1.45% and 0.88%, respectively, and underperformed the Frontline Index.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	74267.34	(508.40)	(0.68)
Nifty50	23382.60	(165.15)	(0.70)
Nifty Midcap 100	60827.95	(895.85)	(1.45)
Nifty Small Cap 100	17979.80	(159.00)	(0.88)

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY IT	29854.25	774.10	2.66
NIFTY MEDIA	1427.55	19.25	1.37
NIFTY DEFENCE	8924.50	(183.00)	(2.01)
NIFTY FMCG	48247.70	(1135.65)	(2.30)

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
TECH MAHINDRA	1543.20	4.00	HUL	2084.30	(3.21)
INFY	1202.50	3.58	TATA CONSUMER	1143.30	(2.98)
COAL INDIA	472.60	3.21	SHRIRAM FINANCE	919.05	(2.97)
TCS	2297.40	1.70	MAX HEALTHCARE	938.45	(2.76)

INDICES LEVELS FOR June 02, 2026

Nifty (future)	
Resistance	23580
Support	23380

Bank Nifty (future)	
Resistance	54350
Support	53440



KEY TAKEAWAYS OF THE DAY

◆ **Lupin wins FDA approval for generic Sutab tabs:**

The company received approval from the USFDA for its abbreviated new drug application for sodium sulfate, magnesium sulfate, and potassium chloride tablets, 1.479g/0.225g/0.188g. The approved tablets are bioequivalent to Sutab Tablets, the reference listed drug (RLD) of Azurity Pharmaceuticals. The medication is indicated for colon cleansing as a preparation for colonoscopy procedures in adults. The company is the exclusive first-to-file applicant for this product, making it eligible for 180 days of generic drug exclusivity in the US market.

◆ **PNC Infratech bags Rs302cr order from AAI in Uttarakhand:**

PNC Infratech has been declared the L1 bidder for an engineering, procurement and construction (EPC) project worth Rs302.44cr, excluding GST, awarded by the Airports Authority of India (AAI). The execution timeline for the project has been set at 24 months. The scope also includes extension and strengthening of runway, apron, taxiways, isolation bay, RESA, grading, civil and electrical works for NAV-AIDS facilities, perimeter road, approach road, runway lighting system, and allied works at Pantnagar Airport in Uttarakhand on an EPC basis.

◆ **Wockhardt secures USFDA approval for antibiotic Zaynich:**

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received USFDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

◆ **NLC India, RIL to jointly develop lignite gasification project in Gujarat:**

NLC India and Reliance Industries will jointly explore developing an underground lignite gasification project in Gujarat as part of efforts to augment domestic gasified fuel supplies amid the global fuel crunch. The public sector undertaking has signed an agreement with RIL to assess the feasibility and technical viability of converting lignite reserves through underground gasification.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

